Re­vamp com­ing at Gilead; Lat­est from in Ukraine, Rus­sia; Bio­gen’s hang­ing bud­get ax; No­var­tis places gene ther­a­py bet; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Amid a big Omi­cron out­break here in Hong Kong, I re­cent­ly caught Covid-19 but thank­ful­ly on­ly had mild symp­toms and have al­ready re­cov­ered. Still, the ex­pe­ri­ence gave me even more ap­pre­ci­a­tion of rapid anti­gen tests and vac­cines — and the peo­ple in this in­dus­try be­hind those very re­al med­ical prod­ucts shap­ing our lives. Have a good week­end.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER